Cervical Human Papillomavirus Testing: Current and Future Impact on Patient Care.
Cervical cancer
FDA
Human papillomavirus
Molecular
Self-collection
Journal
Surgical pathology clinics
ISSN: 1875-9157
Titre abrégé: Surg Pathol Clin
Pays: United States
ID NLM: 101491209
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
12
8
2024
Statut:
ppublish
Résumé
Cervical cancer is the fourth most common malignancy in women worldwide. The identification of human papillomavirus (HPV) as the main etiologic cause of cervical cancer has led to the development and adaptation of HPV molecular diagnostics as a cervical cancer screening and prevention tool. This article highlights six Food and Drug Administration-approved HPV molecular platforms, each with unique advantages and disadvantages. In addition, HPV vaccination and the emergence of HPV self-collection as an alternative testing strategy are discussed.
Identifiants
pubmed: 39129141
pii: S1875-9181(24)00017-5
doi: 10.1016/j.path.2024.04.006
pii:
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
431-439Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors declare no conflicts of interest.